Van Leenders GJLH, Van Der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, et al. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol. 2020;44:e87.

Article  PubMed  PubMed Central  Google Scholar 

Epstein JI, Amin MB, Fine SW, Algaba F, Aron M, Baydar DE, et al. The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer. Arch Pathol Lab Med. 2021;145:461–93.

Article  PubMed  Google Scholar 

Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, et al. Platinum priority-prostate cancer a prostate cancer “‘Nimbosus’”: Genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies. https://doi.org/10.1016/j.eururo.2017.04.034.

Bernardino RM, Carvalho R, Severo L, Alves M, Papoila AL, Pinheiro C. Prostate cancer with cribriform pattern: exclusion criterion for active surveillance? Arch Ital Urol Androl. 2020;92:235–8.

Article  CAS  Google Scholar 

Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, Van Der Kwast TH, Van Leenders GJLH. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol. 2015;28:457–64.

Article  PubMed  Google Scholar 

Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Helleman J, Roobol MJ, et al. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. Mod Pathol. 2019;32:139–46.

Article  PubMed  CAS  Google Scholar 

Bernardino R, Sayyid RK, Lajkosz K, Al-Daqqaq Z, Tiwari R, Cockburn J, et al. Intraductal prostate cancer affinity for lymphatic-predominant metastases through 18F-DCFPyL‒prostate-specific membrane antigen‒positron emission Tomography/CT scans in pretreatment prostate cancer patients. J Urol [Internet]. https://pubmed.ncbi.nlm.nih.gov/38299501/.

Bernardino R, Sayyid RK, Al-Daqqaq Z, Tiwari R, Cockburn J, Vijayakanthan S, et al. Lymphotropic pattern of prostate-specific membrane antigen–detected metastases among biochemically recurrent radical prostatectomy patients with cribriform disease. Eur Urol Focus [Internet]. 2023. http://www.eu-focus.europeanurology.com/article/S2405456923001165/fulltext.

Masoomian M, Downes MR, Sweet J, Cheung C, Evans AJ, Fleshner N, et al. Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. Histopathology. 2019;74:474–82.

Article  PubMed  Google Scholar 

Hollemans E, Verhoef EI, Bangma CH, Schoots I, Rietbergen J, Helleman J, et al. Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens. Histopathology. 2019;75:338–45.

Article  PubMed  PubMed Central  Google Scholar 

Cornford P, Tilki D, Bergh RCN van den, Briers E, Eberli D, Meerleer G De, et al. Prostate cancer EAU guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3. https://uroweb.org/guidelines.

Bernardino R, Sayyid RK, Leão R, Zlotta AR, van der Kwast T, Klotz L, et al. Increasing trend of utilising active surveillance for Gleason Score 7 (3 + 4) prostate cancer. BJU Int [Internet]. 2023. https://pubmed.ncbi.nlm.nih.gov/37606994/.

Trudel D, Downes MR, Sykes J, Kron KJ, Trachtenberg J, Van Der Kwast TH. Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. Eur J Cancer. 2014;50:1610–6.

Article  PubMed  Google Scholar 

Bernardino RM, Sayyid RK, Lajkosz K, Al-Daqqaq Z, Cockburn JG, Chavarriaga J, et al. Limitations of prostate biopsy in detection of cribriform and intraductal prostate cancer. Eur Urol Focus [Internet]. 2023. https://pubmed.ncbi.nlm.nih.gov/37696743/.

Leo P, Chandramouli S, Farré X, Elliott R, Janowczyk A, Bera K, et al. Computationally derived cribriform area index from prostate cancer hematoxylin and eosin images is associated with biochemical recurrence following radical prostatectomy and is most prognostic in Gleason grade group 2. Eur Urol Focus. 2021;7:722–32.

Article  PubMed  PubMed Central  Google Scholar 

Van Leenders GJLH, Van Der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, et al. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol. 2020;44:E87–99.

Article  PubMed  PubMed Central  Google Scholar 

Bernardino R, Sayyid RK, Leão R, Zlotta AR, Kwast T van der, Klotz L, et al. Using active surveillance for Gleason 7 (3+4) prostate cancer: A narrative review. Canadian Urological Association Journal [Internet]. 2023 Dec 21 [cited 2024 Jan 4];18. Available from: https://cuaj.ca/index.php/journal/article/view/8539.

Bernardino R, Fleshner N. Re: sensitivity of multiparametric MRI and targeted biopsy for detection of adverse pathologies (cribriform Gleason pattern 4 and intraductal carcinoma): correlation of detected and missed prostate cancer foci with whole mount histopathology. Eur Urol [Internet]. 2023. https://pubmed.ncbi.nlm.nih.gov/36792385/.

Belue MJ, Blake Z, Yilmaz EC, Lin Y, Harmon SA, Nemirovsky DR, et al. Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI? Prostate. 2023;83:1519–28.

Article  PubMed  CAS  Google Scholar 

Mikoshi A, Miyai K, Hamabe F, Edo H, Ito K, Matsukuma S, et al. MRI-detectability and histological factors of prostate cancer including intraductal carcinoma and cribriform pattern. Prostate. 2022;82:452–63.

Article  PubMed  Google Scholar